{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:01:51Z","timestamp":1790899311099,"version":"4.1.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100005329","name":"Guizhou Provincial Natural Science Foundation","doi-asserted-by":"crossref","award":["China [ZK (2022)key040]"],"award-info":[{"award-number":["China [ZK (2022)key040]"]}],"id":[{"id":"10.13039\/501100005329","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Key Laboratory for Cancer Prevention and treatment of Guizhou Province","award":["QKHPT[2025]031"],"award-info":[{"award-number":["QKHPT[2025]031"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["NS24106"],"award-info":[{"award-number":["NS24106"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Apoptosis"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s10495-025-02215-9","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T12:53:30Z","timestamp":1779281610000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["HMGB1 blockade attenuates cardiac injury induced by radiotherapy combined with PD-1 inhibitor while maintaining the anti-tumor efficacy"],"prefix":"10.1007","volume":"31","author":[{"given":"Yao","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingfeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bibo","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaofen","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinxiang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenneng","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengfa","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"key":"2215_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms231810617","author":"Z Liang","year":"2022","unstructured":"Liang Z, He Y, Hu X (2022) Cardio-oncology: mechanisms, drug combinations, and reverse cardio-oncology. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms231810617","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2215_CR2","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.trecan.2021.10.003","volume":"8","author":"KB Pointer","year":"2022","unstructured":"Pointer KB, Pitroda SP, Weichselbaum RR (2022) Radiotherapy and immunotherapy: open questions and future strategies. Trends Cancer 8(1):9\u201320","journal-title":"Trends Cancer"},{"issue":"2","key":"2215_CR3","doi-asserted-by":"publisher","first-page":"765","DOI":"10.7150\/ijbs.91295","volume":"20","author":"W Shi","year":"2024","unstructured":"Shi W, Tanzhu G, Chen L, Ning J, Wang H, Xiao G et al (2024) Radiotherapy in preclinical models of brain metastases: a review and recommendations for future studies. Int J Biol Sci 20(2):765\u2013783","journal-title":"Int J Biol Sci"},{"issue":"46","key":"2215_CR4","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202303803","volume":"19","author":"M Yu","year":"2023","unstructured":"Yu M, Xie W, Tang Z, Luo J, Liu Y (2023) Radiopaque and X-ray-responsive nanomedicine for preventive therapy of radiation-induced heart disease. Small 19(46):e2303803","journal-title":"Small"},{"issue":"19","key":"2215_CR5","doi-asserted-by":"publisher","first-page":"4353","DOI":"10.1002\/cncr.33083","volume":"126","author":"GA Durm","year":"2020","unstructured":"Durm GA, Jabbour SK, Althouse SK, Liu Z, Sadiq AA, Zon RT et al (2020) A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non-small cell lung cancer: Hoosier cancer research network LUN 14\u2013179. Cancer 126(19):4353\u20134361","journal-title":"Cancer"},{"issue":"9","key":"2215_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamaoncol.2021.2301","volume":"7","author":"SK Jabbour","year":"2021","unstructured":"Jabbour SK, Lee KH, Frost N, Breder V, Kowalski DM, Pollock T et al (2021) Pembrolizumab plus concurrent chemoradiation therapy in patients with unresectable, locally advanced, stage iii non-small cell lung cancer: the phase 2 KEYNOTE-799 nonrandomized trial. JAMA Oncol 7(9):1\u20139","journal-title":"JAMA Oncol"},{"issue":"9","key":"2215_CR7","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1001\/jamaoncol.2019.1478","volume":"5","author":"W Theelen","year":"2019","unstructured":"Theelen W, Peulen HMU, Lalezari F, van der Noort V, de Vries JF, Aerts J et al (2019) Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: results of the PEMBRO-RT phase 2 randomized clinical trial. JAMA Oncol 5(9):1276\u20131282","journal-title":"JAMA Oncol"},{"key":"2215_CR8","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.lungcan.2019.05.001","volume":"133","author":"S Peters","year":"2019","unstructured":"Peters S, Felip E, Dafni U, Belka C, Guckenberger M, Irigoyen A et al (2019) Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer: the ETOP NICOLAS trial. Lung Cancer 133:83\u201387","journal-title":"Lung Cancer"},{"issue":"10","key":"2215_CR9","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMc1900407","volume":"380","author":"YH Kim","year":"2019","unstructured":"Kim YH (2019) Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med 380(10):989\u2013990","journal-title":"N Engl J Med"},{"issue":"18","key":"2215_CR10","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","volume":"375","author":"DB Johnson","year":"2016","unstructured":"Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y et al (2016) Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med 375(18):1749\u20131755","journal-title":"N Engl J Med"},{"issue":"12","key":"2215_CR11","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","volume":"19","author":"JE Salem","year":"2018","unstructured":"Salem JE, Manouchehri A, Moey M, Lebrun-Vignes B, Bastarache L, Pariente A et al (2018) Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol 19(12):1579\u20131589","journal-title":"Lancet Oncol"},{"issue":"10","key":"2215_CR12","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.7150\/ijbs.35460","volume":"15","author":"H Wang","year":"2019","unstructured":"Wang H, Wei J, Zheng Q, Meng L, Xin Y, Yin X, Jiang X (2019) Radiation-induced heart disease: a review of classification, mechanism and prevention. Int J Biol Sci 15(10):2128\u20132138","journal-title":"Int J Biol Sci"},{"issue":"4","key":"2215_CR13","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.jtho.2017.12.002","volume":"13","author":"S Du","year":"2018","unstructured":"Du S, Zhou L, Alexander GS, Park K, Yang L, Wang N et al (2018) PD-1 modulates radiation-induced cardiac toxicity through cytotoxic T lymphocytes. J Thorac Oncol 13(4):510\u2013520","journal-title":"J Thorac Oncol"},{"issue":"3","key":"2215_CR14","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1182\/blood-2009-02-206870","volume":"114","author":"Y Lee","year":"2009","unstructured":"Lee Y, Auh SL, Wang Y, Burnette B, Wang Y, Meng Y et al (2009) Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood 114(3):589\u2013595","journal-title":"Blood"},{"issue":"4","key":"2215_CR15","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1158\/2326-6066.CIR-14-0196","volume":"3","author":"AB Sharabi","year":"2015","unstructured":"Sharabi AB, Nirschl CJ, Kochel CM, Nirschl TR, Francica BJ, Velarde E et al (2015) Stereotactic radiation therapy augments antigen-specific PD-1-mediated antitumor immune responses via cross-presentation of tumor antigen. Cancer Immunol Res 3(4):345\u2013355","journal-title":"Cancer Immunol Res"},{"issue":"24","key":"2215_CR16","doi-asserted-by":"publisher","first-page":"21671","DOI":"10.1021\/acs.jmedchem.4c01912","volume":"67","author":"P Shen","year":"2024","unstructured":"Shen P, Zhang L, Jiang X, Yu B, Zhang J (2024) Targeting HMGB1 and its interaction with receptors: challenges and future directions. J Med Chem 67(24):21671\u201321694","journal-title":"J Med Chem"},{"issue":"1","key":"2215_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s10020-018-0023-8","volume":"24","author":"M He","year":"2018","unstructured":"He M, Bianchi ME, Coleman TR, Tracey KJ, Al-Abed Y (2018) Exploring the biological functional mechanism of the HMGB1\/TLR4\/MD-2 complex by surface plasmon resonance. Mol Med 24(1):21","journal-title":"Mol Med"},{"issue":"4","key":"2215_CR18","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1093\/cvr\/cvx012","volume":"113","author":"K Nishida","year":"2017","unstructured":"Nishida K, Otsu K (2017) Inflammation and metabolic cardiomyopathy. Cardiovasc Res 113(4):389\u2013398","journal-title":"Cardiovasc Res"},{"issue":"1","key":"2215_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-90636-2","volume":"11","author":"JM Choi","year":"2021","unstructured":"Choi JM, Baek SE, Kim JO, Jeon EY, Jang EJ, Kim CD (2021) 5-LO-derived LTB4 plays a key role in MCP-1 expression in HMGB1-exposed VSMCs via a BLTR1 signaling axis. Sci Rep 11(1):11100","journal-title":"Sci Rep"},{"key":"2215_CR20","doi-asserted-by":"publisher","first-page":"6357","DOI":"10.2147\/JIR.S384279","volume":"15","author":"J Bai","year":"2022","unstructured":"Bai J, Wu B, Zhao S, Wang G, Su S, Lu B et al (2022) The effect of PD-1 inhibitor combined with irradiation on HMGB1-associated inflammatory cytokines and myocardial injury. J Inflamm Res 15:6357\u20136371","journal-title":"J Inflamm Res"},{"issue":"6","key":"2215_CR21","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.13048","volume":"54","author":"W Feng","year":"2021","unstructured":"Feng W, Wang J, Yan X, Zhang Q, Chai L, Wang Q et al (2021) ERK\/Drp1-dependent mitochondrial fission contributes to HMGB1-induced autophagy in pulmonary arterial hypertension. Cell Prolif 54(6):e13048","journal-title":"Cell Prolif"},{"issue":"20","key":"2215_CR22","doi-asserted-by":"publisher","first-page":"8436","DOI":"10.1074\/jbc.M116.769380","volume":"292","author":"T Horiuchi","year":"2017","unstructured":"Horiuchi T, Sakata N, Narumi Y, Kimura T, Hayashi T, Nagano K et al (2017) Metformin directly binds the alarmin HMGB1 and inhibits its proinflammatory activity. J Biol Chem 292(20):8436\u20138446","journal-title":"J Biol Chem"},{"issue":"5","key":"2215_CR23","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1002\/hep.28736","volume":"64","author":"P Lundb\u00e4ck","year":"2016","unstructured":"Lundb\u00e4ck P, Lea JD, Sowinska A, Ottosson L, F\u00fcrst CM, Steen J et al (2016) A novel high mobility group box 1 neutralizing chimeric antibody attenuates drug-induced liver injury and postinjury inflammation in mice. Hepatology 64(5):1699\u20131710","journal-title":"Hepatology"},{"issue":"7","key":"2215_CR24","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1084\/jem.20052203","volume":"203","author":"S Qin","year":"2006","unstructured":"Qin S, Wang H, Yuan R, Li H, Ochani M, Ochani K et al (2006) Role of HMGB1 in apoptosis-mediated sepsis lethality. J Exp Med 203(7):1637\u20131642","journal-title":"J Exp Med"},{"issue":"18","key":"2215_CR25","doi-asserted-by":"publisher","first-page":"13439","DOI":"10.1021\/acs.jmedchem.1c00852","volume":"64","author":"J Sgrignani","year":"2021","unstructured":"Sgrignani J, Cecchinato V, Fassi EMA, D\u2019Agostino G, Garofalo M, Danelon G et al (2021) Systematic development of peptide inhibitors targeting the CXCL12\/HMGB1 interaction. J Med Chem 64(18):13439\u201313450","journal-title":"J Med Chem"},{"issue":"7","key":"2215_CR26","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/s41568-022-00462-5","volume":"22","author":"SM Man","year":"2022","unstructured":"Man SM, Jenkins BJ (2022) Context-dependent functions of pattern recognition receptors in cancer. Nat Rev Cancer 22(7):397\u2013413","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"2215_CR27","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1038\/nm1622","volume":"13","author":"L Apetoh","year":"2007","unstructured":"Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A et al (2007) Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 13(9):1050\u20131059","journal-title":"Nat Med"},{"issue":"1","key":"2215_CR28","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/imr.13271","volume":"321","author":"C Galassi","year":"2024","unstructured":"Galassi C, Klapp V, Yamazaki T, Galluzzi L (2024) Molecular determinants of immunogenic cell death elicited by radiation therapy. Immunol Rev 321(1):20\u201332","journal-title":"Immunol Rev"},{"issue":"1","key":"2215_CR29","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/s41392-021-00507-5","volume":"6","author":"P Yu","year":"2021","unstructured":"Yu P, Zhang X, Liu N, Tang L, Peng C, Chen X (2021) Pyroptosis: mechanisms and diseases. Signal Transduct Target Ther 6(1):128","journal-title":"Signal Transduct Target Ther"},{"issue":"7575","key":"2215_CR30","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/nature15514","volume":"526","author":"J Shi","year":"2015","unstructured":"Shi J, Zhao Y, Wang K, Shi X, Wang Y, Huang H et al (2015) Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature 526(7575):660\u2013665","journal-title":"Nature"},{"issue":"1","key":"2215_CR31","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1186\/s12964-024-01966-3","volume":"22","author":"Y Liu","year":"2024","unstructured":"Liu Y, Wang D, Liu X, Yuan H, Liu D, Hu Y, Ning S (2024) Biological and pharmacological roles of pyroptosis in pulmonary inflammation and fibrosis: recent advances and future directions. Cell Commun Signal 22(1):586","journal-title":"Cell Commun Signal"},{"key":"2215_CR32","doi-asserted-by":"publisher","DOI":"10.1007\/s10753-024-02056-9","author":"B Wu","year":"2024","unstructured":"Wu B, Zhao S, Zhang J, Liu Y, Bai J, Wang G et al (2024) PD-1 inhibitor aggravate irradiation-induced myocardial fibrosis by regulating TGF-\u03b21\/Smads signaling pathway via GSDMD-mediated pyroptosis. Inflammation. https:\/\/doi.org\/10.1007\/s10753-024-02056-9","journal-title":"Inflammation"},{"key":"2215_CR33","doi-asserted-by":"publisher","DOI":"10.15616\/BSL.2014.20.3.147","author":"NK Lee","year":"2014","unstructured":"Lee NK, Kim HS (2014) Comparison analysis of immune cells between CT26 tumor bearing mice and normal mice. Biomed Sci Lett. https:\/\/doi.org\/10.15616\/BSL.2014.20.3.147","journal-title":"Biomed Sci Lett"},{"key":"2215_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.118392","volume":"260","author":"LG Fernandes","year":"2020","unstructured":"Fernandes LG, Tobias GC, Paix\u00e3o AO, Dourado PM, Voltarelli VA, Brum PC (2020) Exercise training delays cardiac remodeling in a mouse model of cancer cachexia. Life Sci 260:118392","journal-title":"Life Sci"},{"issue":"12","key":"2215_CR35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0226440","volume":"14","author":"TE Berent","year":"2019","unstructured":"Berent TE, Dorschner JM, Meyer T, Craig TA, Wang X, Kunz H et al (2019) Impaired cardiac performance, protein synthesis, and mitochondrial function in tumor-bearing mice. PLoS ONE 14(12):e0226440","journal-title":"PLoS ONE"},{"issue":"3","key":"2215_CR36","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0167-8140(00)00327-3","volume":"58","author":"JJ Kr\u00fcse","year":"2001","unstructured":"Kr\u00fcse JJ, Zurcher C, Strootman EG, Bart CI, Schlagwein N, Leer JW, Wondergem J (2001) Structural changes in the auricles of the rat heart after local ionizing irradiation. Radiother Oncol 58(3):303\u2013311","journal-title":"Radiother Oncol"},{"issue":"3","key":"2215_CR37","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.jaccao.2021.06.007","volume":"3","author":"C Bergom","year":"2021","unstructured":"Bergom C, Bradley JA, Ng AK, Samson P, Robinson C, Lopez-Mattei J, Mitchell JD (2021) Past, present, and future of radiation-induced cardiotoxicity: refinements in targeting, surveillance, and risk stratification. JACC CardioOncol 3(3):343\u2013359","journal-title":"JACC CardioOncol"},{"issue":"13","key":"2215_CR38","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1200\/JCO.2016.71.6142","volume":"35","author":"RT Dess","year":"2017","unstructured":"Dess RT, Sun Y, Matuszak MM, Sun G, Soni PD, Bazzi L et al (2017) Cardiac events after radiation therapy: combined analysis of prospective multicenter trials for locally advanced non-small-cell lung cancer. J Clin Oncol 35(13):1395\u20131402","journal-title":"J Clin Oncol"},{"issue":"7","key":"2215_CR39","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1001\/jamaoncol.2019.0393","volume":"5","author":"Y Wang","year":"2019","unstructured":"Wang Y, Zhou S, Yang F, Qi X, Wang X, Guan X et al (2019) Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis. JAMA Oncol 5(7):1008\u20131019","journal-title":"JAMA Oncol"},{"key":"2215_CR40","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.lungcan.2019.02.011","volume":"130","author":"Y Sakata","year":"2019","unstructured":"Sakata Y, Kawamura K, Ichikado K, Shingu N, Yasuda Y, Eguchi Y et al (2019) The association between tumor burden and severe immune-related adverse events in non-small cell lung cancer patients responding to immune-checkpoint inhibitor treatment. Lung Cancer 130:159\u2013161","journal-title":"Lung Cancer"},{"issue":"4","key":"2215_CR41","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1093\/eurheartj\/ehab430","volume":"43","author":"L Michel","year":"2022","unstructured":"Michel L, Helfrich I, Hendgen-Cotta UB, Mincu RI, Korste S, Mrotzek SM et al (2022) Targeting early stages of cardiotoxicity from anti-PD1 immune checkpoint inhibitor therapy. Eur Heart J 43(4):316\u2013329","journal-title":"Eur Heart J"},{"key":"2215_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2023.121390","volume":"316","author":"AA Alzokaky","year":"2023","unstructured":"Alzokaky AA, Al-Karmalawy AA, Saleh MA, Abdo W, Farage AE, Belal A et al (2023) Metformin ameliorates doxorubicin-induced cardiotoxicity targeting HMGB1\/TLR4\/NLRP3 signaling pathway in mice. Life Sci 316:121390","journal-title":"Life Sci"},{"key":"2215_CR43","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.freeradbiomed.2022.08.035","volume":"191","author":"Y Liu","year":"2022","unstructured":"Liu Y, Chen L, Gao L, Pei X, Tao Z, Xu Y, Li R (2022) LRRK2 deficiency protects the heart against myocardial infarction injury in mice via the P53\/HMGB1 pathway. Free Radic Biol Med 191:119\u2013127","journal-title":"Free Radic Biol Med"},{"issue":"1","key":"2215_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0898-6","volume":"17","author":"X Zhang","year":"2018","unstructured":"Zhang X, Shi H, Yuan X, Jiang P, Qian H, Xu W (2018) Tumor-derived exosomes induce N2 polarization of neutrophils to promote gastric cancer cell migration. Mol Cancer 17(1):146","journal-title":"Mol Cancer"},{"issue":"6","key":"2215_CR45","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.7150\/thno.92672","volume":"14","author":"SMP Vadevoo","year":"2024","unstructured":"Vadevoo SMP, Kang Y, Gunassekaran GR, Lee SM, Park MS, Jo DG et al (2024) IL4 receptor targeting enables nab-paclitaxel to enhance reprogramming of M2-type macrophages into M1-like phenotype via ROS-HMGB1-TLR4 axis and inhibition of tumor growth and metastasis. Theranostics 14(6):2605\u20132621","journal-title":"Theranostics"},{"issue":"10","key":"2215_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.114886","volume":"43","author":"Z Xu","year":"2024","unstructured":"Xu Z, Ma W, Wang J, Chen H, Li H, Yin Z et al (2024) Nuclear HMGB1 is critical for CD8 T cell IFN-\u03b3 production and anti-tumor immunity. Cell Rep 43(10):114886","journal-title":"Cell Rep"},{"issue":"1","key":"2215_CR47","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1186\/s12974-016-0705-5","volume":"13","author":"X Xiong","year":"2016","unstructured":"Xiong X, Gu L, Wang Y, Luo Y, Zhang H, Lee J et al (2016) Glycyrrhizin protects against focal cerebral ischemia via inhibition of T cell activity and HMGB1-mediated mechanisms. J Neuroinflammation 13(1):241","journal-title":"J Neuroinflammation"},{"issue":"1","key":"2215_CR48","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-021-02126-x","volume":"18","author":"O Oladiran","year":"2021","unstructured":"Oladiran O, Shi XQ, Yang M, Fournier S, Zhang J (2021) Inhibition of TLR4 signaling protects mice from sensory and motor dysfunction in an animal model of autoimmune peripheral neuropathy. J Neuroinflammation 18(1):77","journal-title":"J Neuroinflammation"},{"key":"2215_CR49","doi-asserted-by":"publisher","DOI":"10.3390\/antiox14030256","author":"C Penna","year":"2025","unstructured":"Penna C, Pagliaro P (2025) Endothelial dysfunction: redox imbalance, NLRP3 inflammasome, and inflammatory responses in cardiovascular diseases. Antioxidants. https:\/\/doi.org\/10.3390\/antiox14030256","journal-title":"Antioxidants"},{"issue":"7610","key":"2215_CR50","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nature18629","volume":"535","author":"X Liu","year":"2016","unstructured":"Liu X, Zhang Z, Ruan J, Pan Y, Magupalli VG, Wu H, Lieberman J (2016) Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores. Nature 535(7610):153\u2013158","journal-title":"Nature"},{"issue":"1","key":"2215_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-021-00729-0","volume":"7","author":"G Wang","year":"2021","unstructured":"Wang G, Jin S, Huang W, Li Y, Wang J, Ling X et al (2021) LPS-induced macrophage HMGB1-loaded extracellular vesicles trigger hepatocyte pyroptosis by activating the NLRP3 inflammasome. Cell Death Discov 7(1):337","journal-title":"Cell Death Discov"},{"key":"2215_CR52","doi-asserted-by":"publisher","first-page":"7295","DOI":"10.2147\/JIR.S336626","volume":"14","author":"W Hou","year":"2021","unstructured":"Hou W, Wei X, Liang J, Fang P, Ma C, Zhang Q, Gao Y (2021) HMGB1-induced hepatocyte pyroptosis expanding inflammatory responses contributes to the pathogenesis of acute-on-chronic liver failure (ACLF). J Inflamm Res 14:7295\u20137313","journal-title":"J Inflamm Res"}],"container-title":["Apoptosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10495-025-02215-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10495-025-02215-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10495-025-02215-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T20:13:15Z","timestamp":1782850395000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10495-025-02215-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":52,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["2215"],"URL":"https:\/\/doi.org\/10.1007\/s10495-025-02215-9","relation":{},"ISSN":["1360-8185","1573-675X"],"issn-type":[{"value":"1360-8185","type":"print"},{"value":"1573-675X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,21]]},"assertion":[{"value":"28 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Experiments were approved by the Ethics Committee of Guizhou Medical University.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All authors approved the manuscript for publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"149"}}